Enhancing Recovery after Radical Prostatectomy

At Levee Medical®, we are committed to designing solutions that aim to reduce complications associated with surgical treatment.

One in Eight Men Infographic

One in 8 men will develop prostate cancer*

Patients often choose surgery to treat prostate cancer

In most cases, surgery enables complete and immediate removal of cancer.

Caution Icon

Urinary incontinence after prostatectomy remains a debilitating problem

It is the most feared complication following surgery for prostate cancer.

Life after prostatectomy deserves to be brilliant

Our goal is to minimize incontinence so that patients can turn the page after prostate cancer surgery.

Introducing

Voro® Urologic Scaffold

Transforming prostatectomy recovery with the first and only absorbable device specifically engineered to address urinary incontinence head-on.

CLINICAL EVIDENCE

Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of 2 Cases, Urologia Internationalis

 

The Levee Medical Voro prostatectomy implant is not approved for sale worldwide. It is not FDA-cleared or approved. It is currently in the research and development phase and is not available for sale in any country. 
Content is intended for healthcare professionals. 

Team

Adam Irving

Bruce Choi

Founder, Director, CTO & Chairman

Adam Irving

Adam Irving

CEO & Director

Kevin Hopkins

Kevin Hopkins

Vice President, Quality

Kevin Hopkins

Karen Cornett

Vice President, Clinical Affairs


Gary McCord

Sean Collins

Vice President,
Market Development

Mike McKellar

Mike McKellar

Corporate Controller

Gary McCord

Mike Henson

Director

Gary McCord

Gary McCord

Director

Peter Mulrooney

Peter Mulrooney

Director

News

Levee Medical® to Accelerate Development of its Voro® Urologic Scaffold, Designed to Improve Post-Prostatectomy Recovery Outcomes

Additionally, Company Reaches Significant Enrollment Milestones in Feasibility and Observational Studies

Durham, NC – June 10, 2024 – Levee Medical®, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has received significant funding commitments to support ongoing regulatory and clinical activities. The funds raised will be instrumental in advancing the development of the Voro® Urologic Scaffold and supporting broader clinical studies to further establish its safety and efficacy.

read more

Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes

Milestone Achieved as Company Announces Successful Enrollment of First Patients in its First-in-Human (FIH) Study

DURHAM, NC – Sept. 6, 2023 – Levee Medical, a clinical-stage medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has raised a total of $4.3 million in oversubscribed funds. Additionally, Levee Medical successfully treated the first study participants in its first-in-human (FIH) study, demonstrating initial safety data for the Voro Urologic Scaffold.

read more

Levee Medical™ Announces the Closing of $6.6m Series A Financing

Company to Accelerate Development of Novel Urologic Device Designed to Improve Recovery Outcomes Post-Prostatectomy

Durham, NC – August 23, 2022 – Levee Medical, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has closed an initial oversubscribed series A financing round, raising a total of $6.6 million. The funds will be used to advance product development, scale infrastructure, and expand the team to support the development of the company’s Voro Urologic Scaffold, a bioresorbable post-prostatectomy implant.

read more

If you are interested in learning more about being considered as a potential clinical site, please send us a note.